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ISO 9002 Certificate foSummary Metered inhalers using chlorofluorocarbon (CFC) propellents have been
gradually replaced by new devices that use hydrofluoroalkanes (HFAs) as their
propellents, which are less harmful to the environment. This reformulation led to a
substantial improvement of the previous technologies applied to inhalation devices
and of the physical characteristics of drugs delivered. In particular, inhaled
corticosteroids, such as beclomethasone dipropionate (BDP) which is of fundamental
importance in the long-term management of bronchial asthma, took advantage of
this reformulation.
Unlike the preparation beclomethasone dipropionate and chlorofluorocarbon
(BDP-CFC) which was a suspension, that of beclomethasone dipropionate and a
hydrofluoroalkane (BDP-HFA) is a solution and produces an aerosol with a mean
aerodynamic particle size of 1.1mm, which is much smaller than the particle size of
3.5–4.0mm, obtained with the BDP-CFC. The particles of BDP-HFA can then deposit in
the lungs in a larger amount, and particularly in the more peripheral airways where
the inflammatory process starts in the case of bronchial asthma.
A 12-week use of BDP-HFA ensured a significant better control of the bronchial
response to methacholine (MCh) than the corresponding use of BDP-CFC for the same
duration. The therapeutic performance of BDP-HFA proved much higher and allowed
the substantial reduction of the therapeuticdaily dose for the clinical asthma
management, being the increased and more peripheral deposition of BDP-HFA is
presumed to play a crucial role.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Inhaled corticosteroids are the cornerstones of
asthma treatment, independently of the clinical
severity of asthma.1 It has been proved that their
prolonged use leads to the control of clinical
symptoms, of respiratory function, and of bronchial
hyperreactivity, which is a peculiar feature of
asthma and is closely related to the presence of
airway inflammation.2
Beclomethasone dipropionate (BDP), a drug
belonging to the class of corticosteroids, was the
first synthetic corticosteroid delivered to asth-
matics per inhalation and it still is one of the most
widely used steroids for this purpose.
According to the regular formulation, BDP con-
sists in a suspension with a chlorofluorocarbon
(CFC) propellent which is delivered by a metered-
dose inhaler (MDI). However, it is well known that
the pulmonary deposition of such a metered
preparation with the CFC propellent is poor and
only a small part of the active drug actually can
reach the airways.3 Moreover, it has long been
known that CFCs are harmful to the environment
because they contribute to deplete the ozone
layer.4
In order to replace CFCs, BDP has been reformu-
lated with a new propellent, such as the hydro-
fluoroalkane (HFA) 134a, which is free of chlorine
and is much less harmful to the environment.5 This
new development contributed to further improve
the technologies for inhalation devices to a large
extent, together with the knowhow on the physical
properties of inhaled drugs, and their deposition
pattern in the airways. It was also assumed that this
new improvement could reduce the level of
bronchial hyperreactivity to non-specific stimuli.
The aim of the present study was to compare the
effects of BDP-CFC 1000 mg/day and of BDP-HFA
400 mg/day on the bronchial response to methacho-BDP-CFC - 1000 µg/day (n = 8)     
BDP-HFA - 400 µg/day (n = 7) 
   12 weeks  4 week
wash-ou
Figure 1 Experimentalline (MCh) in mild persistent asthmatics treated for
12 weeks.Materials and method
The study was carried out according to a rando-
mized, double-blind, cross-over design. Both treat-
ments had a 12-week duration, with a 4-week
wash-out period in- between (see Fig. 1). The
wash-out period was considered long enough to re-
establish the original bronchial response to MCh.6
Only the use of short-acting b2 adrenergic agents
was allowed, whenever needed, during the wash-
out period.
During the study, the patients’ compliance to
both treatments was calculated in terms of % of the
prescribed daily dose, and diaries were supplied to
all patients. Compliance was accepted as
’ ’
suffi-
cient’’ when X75% of treatment was assumed.7
Inclusion criteria were:s 
t 
deage X18 years, of both sex;
 non-smoker;
 naı¨ve to steroids;
 baseline FEV1X80% predicted;
 baseline PD20 FEV1 MChp800 mg;
 use of short-acting b2 adrenergics prn; no treatment with antihistamines, ketotifen,
chromones, theophylline and leucotriene recep-
tor antagonists in the previous 4 weeks; no exacerbation in the previous 4 weeks.
Further exclusion criteria were: pregnancy or breast feeding;
 serious systemic disorders;
 regular users of b-blockers, nitrates or antic-
oagulants;
 antibiotic treatment in the previous 4 weeks;   12 weeks 
BDP-CFC - 1000 µg/day
BDP-HFA 400 µg/day
sign of the study.
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dures of the protocol.
Lung function tests (FEV1, PEF and MMEF25–75)
were carried out with a SyncMaster 510s spirometer
made (Ja¨ger, Germany), being results espressed in
% of the predicted values (CECA).8 All tests were
performed after the wash-out period and at least
6 h after the administration of any short-acting b2
adrenergic.
The bronchial response to MCh was determined
three times in the case of all the patients, namely at
the beginning of the study; after the first treatment
period, and after the second treatment period.
During the 4-week wash-out period in between, only
short-acting b2 adrenergics prn were allowed. The
hyperresponsiveness to MCh was tested according to
the ERS guidelines,9 and the provocation dose was
expressed in mcg of MCh required to induce a 20%
FEV1 drop from baseline (PD20 FEV1). The bronchial
challenge (methacholine Lofarma, Milan, Italy) was
delivered by means of a Mefar MB3 dosimeter
(Brescia, Italy). MCh was administered in doubling
doses after a dose of phosphate buffer, being 50mg
the first MCh dose inhaled, up to the maximal
cumulative dose of 3150mg.Statistics
A Wilcoxon matched-pairs signed-ranks test was
used to compare mean values7SD obtained for all
variables (FEV1, PEF, MMEF, and PD20FEV1 to MCh) at
the end of each treatment period to the corre-
sponding baseline values. The level of compliance
to treatment was also compared in the two groups,
and Po0:05 was the accepted level for statistical
significance.Results
After their informed written consent, 15 non-
smoker, mild persistent asthmatics (8 males, meanTable 1 Spirometric values before and after a 12-week t
standard deviations). The mean value of patient complianc
is no significant difference between the two treatments.
FEV1 PEF
Base-line 102.1715.9 105.57
After BDP-CFC 100.6714.7 109.67
After BDP-HFA 104.6714.5 112.27age 30.1 y710.8 SD, 11 atopics) were studied. Their
lung function in baseline was: FEV1 (forced ex-
piratory volume in 1-s) ¼ 102.1% pred.75.9 SD; PEF
(peak expiratory flow) ¼ 105.5% pred.78.4 SD;
MMEF (maximum mid-expiratory flow 25–75% pul-
monary volume) ¼ 66.2% pred.721.3 SD.
None of the patients had ever been treated with
inhaled corticosteroids and only assumed short-
acting b2 adrenergic drugs when needed. All
patients showed a marked bronchial response to
MCh in baseline, being the PD20
FEV1 ¼ 178.1 mg7185.0 SD (PD20 corresponds to
the cumulative dose of MCh that produces a FEV1
decrease of 20% from baseline).
All patients completed the study. No exacerba-
tion or infection of the upper or lower airways
occurred during both the two treatment periods
and the wash-out period. The overall compliance to
the treatments (such as based on the patients’ own
reports) was 90.3%75.2%, being therefore always
confirmed above the declared threshold of 75%.
Table 1 reports mean values7SD obtained for
each spirometric variable in baseline and following
both treatments, together with the corresponding
level of compliance reached during each treatment
period. No significant difference was observed
between the two treatments (P ¼ n.s.). Also the
level of patients’ compliance was comparable
during the two treatments (P ¼ ns).
Table 2 reports all the individual values of PD20
FEV1 to MCh assessed for each patient in baseline
and following both treatments (such as after BDP-
CFC and after BDP-HFA) together with the corre-
sponding mean values7 SD at the same experimen-
tal times. The results of the statistical comparison
between post-treatment vs. baseline values are
also reported in Table 2.
PD20 FEV1 to MCh slightly changed following a 12-
week treatment with BDP-CFC, being mean base-
line value 178.1 mg7185.0 SD and the corresponding
post-treatment mean value 319.3 mg7332.6 SD ðP ¼
0:0437Þ:
Unlike in the BDP-CFC treated patients, in those
who assumed BDP-HFA for 12 weeks PD20 FEV1 to
MCh changed substantially from 178.1 mg7185.0 SDreatment with BDP-CFC and BDP-HFA (mean values and
e in the two treatment periods is also reported. There
MMEF Compliance
8.4 66.2721.3 —
9.9 72.2726.5 89.876.1
15.4 72.5732.0 90.774.4
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Table 2 Values of PD20 FEV1 recorded at different experimental times together with the statistical significance
of the comparison vs baseline values (mean and standard deviation).
Patient’s initials Base-line MCh dose (mg) MCh dose after BDP-CFC (mg) MCh dose after BDP-HFA (mg)
N.R. 612 544 1786
S.E. 236 49 682
F.M. 181 229 173
N.A. 290 451 191
R.E. 450 950 2638
C.A. 50 66 52
P.A. 95.8 128 749
M.Y. 95 50 50
R.S. 0.05 0.05 165
Z.G. 0.05 5 87
G.I. 400 844 1850
G.S. 0.05 50 408
C.M. 100 436 2100
T.A. 50 173 750
DB.G 112 815 2450
Mean7SD 178.1 mg7185.0 319.3 mg7332.6* 942.0 mg7946.1**,***
P ¼ 0:0437 vs. baseline; P ¼ 0:0059 vs. baseline; P ¼ 0:0045 vs. BDP-CFC.
Effects of HFA- and CFC-beclomethasone dipropionate on bronchial response of MCh in asthma 853in baseline to 942.0 mg7946.1 SD at the end of the
treatment period ðP ¼ 0:0059Þ:
When the two treatments were compared in
terms of bronchial response to MCh, BDP-HFA
proved significantly more effective than BDP-CFC
ðP ¼ 0:0045Þ:Discussion
Inhaled corticosteroids are fundamental to the
management of bronchial asthma1 since they
can generally reduce inflammation and the bron-
chial response of the airways to non-specific
stimuli.2
Inflammation-induced bronchial hyperrespon-
siveness is substantial even in mild bronchial
asthma, since persistent inflammation affects
peripheral airways particularly, being T cells and
eosinophils much more represented than in prox-
imal airways.10
In patho-physiological terms, conventional indi-
cators of lung function cannot inform on the
functional state of small airways (such as those
with a diameter p2mm) specifically, because
they only contribute 10% to the total airflow
resistance. Nevertheless small airways show clear
inflammatory changes since the early stages of
asthma, and all the structural changes deriving may
represent the biological basis for the airway
’ ’
remodelling’’, another peculiar feature of persis-tent asthma.11 Moreover, recent studies tend to
support the hypothesis that the inflammation
of small airways and the thickening of airway
basal membrane may play a crucial role in
determining and supporting bronchial hyperrespon-
siveness.12–15
Therefore, any effective antiasthma drug should
be targeted to all the bronchial tree but particu-
larly to peripheral airways because at this level
occur those biological events which give rise to the
disease, sustain its patho-physiological pattern,
and reflect the progression of the disease.
This kind of therapeutic goal can be pursued and
obtained by improving the engineering of the
devices for the drug delivery, but also by improving
the physical characteristics of the active drug and
of the propellent used.16
Differently from the past, the introduction of
HFAs enabled BDP to be now employed as a solution
rather than as a suspension.
Furthermore, the active substance is now re-
leased by the device as an aerosol constituted of
particles of a much smaller mean diameter (1.1 mm)
than previously (3.5–4 mm), when CFC was the
propellent. Consequently, the respirable fraction of
the active drug is significantly larger, and the
increased pulmonary deposition (both in the cen-
tral and in the peripheral airways) corresponds to a
substantially reduced proportion of the active drug
which stops in the oropharynx.17–18
The BDP therapeutic performance was highly
improved and side effects reduced, particularly in
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HFA, scintigraphic measurements confirmed that
60–70% of the active drug reaches the lungs and is
uniformly distributed in the airways (central,
intermediate and peripheral airways), and that
only 18% deposits in the oropharynx.17 This perfor-
mance is quite different from that of previous BDP-
CFC, when the pulmonary deposition was no more
than 25% and the oropharyngeal deposition of
60–90%.18
The larger respirable fraction of aerosol particles
and the higher pulmonary deposition obtained with
HFA led to the reduction of the BDP daily dose, with
consistent advantages in terms of safety and
tolerability.19 Several studies indicate that BDP-
HFA can be used by halving the doses of BDP-CFC in
adult asthmatics, with equivalent effects on re-
spiratory symptoms.20–22
Also in children it has also been recently found
that BDP-HFA 100–200 mg/day corresponds to BDP-
CFC 200–400 mg/day, delivered by means of an
expansion chamber.23,24
Unlike previous studies on BDP-HFA where FEV1
and PEF were the unique parameters used to assess
the therapeutic performance,20,24 up to now only
one group of authors studied the efficacy of BDP-
HFA in asthmatics on the basis of the bronchial
response to MCh, even though they measured the
solely air trapping by high-resolution computed
axial tomography.25
The present study is the first one at our
knowledge that assessed the effects of ultrafine
BDP on the bronchial hyperresponsiveness to
MCh. Data seem to confirm that BDP-HFA is
much more effective than BDP-CFC even after
only a 12-week treatment: BDP-HFA produces
in fact a systematic and a greater increase
(such as double) in the threshold of MCh
bronchial response. It is probably due to the
particular pattern of pulmonary deposition of
HFA. The BDP-HFA therapeutic performance has in
fact been found to be better than twice as much
BDP-CFC as regards protection from hyperreaction
to MCh.
This medium-term therapeutic performance is
clearly higher to that obtained with the conven-
tional BDP+CFCs. Moreover, the physico-chemical
properties of BDP-HFA, which is a solution, probably
contribute to a much better long-term patient’s
tolerability and compliance.
Concluding, present data seem to confirm that
the new aerosol propellants which facilitate the
active drugs to reach all targets therapeutically
important in the airways are steadily improving the
therapeutic options beyond the standard use of
inhalation corticosteroids.References
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